Drug intelligence / Profile preview

panobinostat + trastuzumab + paclitaxel

Development stage: Unknown
Lead developer: Novartis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral (panobinostat), Intravenous (panobinostat, Trastuzumab, Paclitaxel)

Overview

Panobinostat + trastuzumab + paclitaxel is an investigational drug combination evaluated for the treatment of HER2-positive metastatic breast cancer. Panobinostat is a small molecule histone deacetylase inhibitor (HDAC inhibitor) that disrupts transcriptional processes leading to apoptosis and cell cycle arrest. Trastuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2) and mediates its antitumor effects through blockade of HER2 signaling, antibody-dependent cellular cytotoxicity, and inhibition of HER2-mediated cell proliferation. Paclitaxel is an antineoplastic small molecule that stabilizes microtubules, resulting in inhibition of mitosis and cell division. The combination is being studied for synergistic antitumor effects in HER2+ breast cancer, aiming to overcome resistance and improve clinical outcomes[1][2][3][5][7][10].

Brand names: Taxol (for paclitaxel)Herceptin (for trastuzumab)
Other names: panobinostat + trastuzumab + paclitaxel

Targets

TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)HDAC (HDAC family)

Beyond the preview

Go deeper on panobinostat + trastuzumab + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on panobinostat + trastuzumab + paclitaxel.

Explore the full profile